To analyze the clinical effect of dapagliflozin tables combined with semaglutide injection in the treatment of patients with type 2 diabetes mellitus (T2DM) accompanied by abdominal obesity.

Patients with T2DM accompanied by abdominal obesity were divided into the control group and the treatment group by the random number table method. The control group took dapagliflozin tables orally once a day, 10 mg each time. The treatment group was hypodermic injection with semaglutide injection once a week on the basis of the control group, 0.5 mg each time. Both groups were treated for 3 months. The lipid metabolism, glucose metabolism, body mass index (BMI), waist circumference(WC), serological indicators, adipokines and adverse drug reactions were compared between the 2 groups.

In this study, 84 cases were enrolled in the treatment group and 83 cases in the control group, and 3 cases fell off in both groups. Finally, 81 cases were enrolled in the treatment group and 80 cases in the control group. After treatment, the low-density lipoprotein cholesterol (LDL-C) in the treatment group and the control group were (3.21±0.43) and (3.57±0.54) mmol·L^-1, respectively, and the glycated hemoglobin (HbAlc) were (5.42±0.67)% and (6.95±0.75)%, respectively; the homeostasis model assessment of insulin resistance (HOMA-IR) were (2.02±0.37) and (2.45±0.48) respectively, the BMI were (26.02±2.11) and (27.12±2.38) kg·m^-2, respectively, and the WC were (90.25±8.17) and (95.07±9.14) cm, respectively; insulin-like growth factor (IGF) were (154.31±15.68) and (165.23±17.08) mmol·L^-1, respectively, and asprosin (ASP) were (1.20±0.31) and (1.37±0.38) μg·L^-1, respectively; the spexin (SPX) were (0.78±0.19) and (0.65±0.14) ng·mL^-1, respectively, while the difference of above indexes in treatment and control groups were all statistically significant (all P<0.05). The adverse drug reaction incidence in treatment and control groups were 8.64% and 5.00%, respectively, showing no statistically significant difference (P>0.05).

Dapagliflozin tables combined with semaglutide injection can effectively regulate the glycolipid metabolism of patients with type 2 diabetes mellitus (T2DM) accompanied by abdominal obesity, reduce BMI and WC, regulate adipokines, inhibit the expression of serum IGF, and with reliable safety.